Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Safety of Herpes Zoster Vaccine in Psoriasis Patients on Biologic Therapies

Safety of Herpes Zoster Vaccine in Psoriasis Patients on Biologic Therapies Herpes zoster (HZ) is a blistering, dermatomal cutaneous eruption caused by the reactivation of varicella zoster virus. The incidence of HZ increases exponentially with age and is commonly seen in adults >60 years of age. Patients with psoriasis on biologic therapies have ≍2 times the risk of developing HZ compared with the general population. The approval of HZ vaccine by the US Food and Drug Administration in 2006 has significantly reduced the incidence of HZ and postherpetic neuralgia by 61.1% and 66.5%, respectively. However, this live vaccine is not currently recommended for immunocompromised patients, such as individuals with psoriasis on biologics. Two major concerns with live vaccinations in this patient population include the risk of impaired immunologic response and the increased incidence of HZ and its complications. However, recent evidence has shown that, despite these concerns, vaccinating patients with psoriasis on biologics with an HZ vaccine can be both safe and effective. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Psoriasis and Psoriatic Arthritis SAGE

Safety of Herpes Zoster Vaccine in Psoriasis Patients on Biologic Therapies

Download PDF
3 pages

Loading next page...
 
/lp/sage/safety-of-herpes-zoster-vaccine-in-psoriasis-patients-on-biologic-0rMNm0HCiR

References (27)

Publisher
SAGE
Copyright
© 2013 National Psoriasis Foundation
ISSN
1089-3504
eISSN
1557-3168
DOI
10.1177/247553031319a00201
Publisher site
See Article on Publisher Site

Abstract

Herpes zoster (HZ) is a blistering, dermatomal cutaneous eruption caused by the reactivation of varicella zoster virus. The incidence of HZ increases exponentially with age and is commonly seen in adults >60 years of age. Patients with psoriasis on biologic therapies have ≍2 times the risk of developing HZ compared with the general population. The approval of HZ vaccine by the US Food and Drug Administration in 2006 has significantly reduced the incidence of HZ and postherpetic neuralgia by 61.1% and 66.5%, respectively. However, this live vaccine is not currently recommended for immunocompromised patients, such as individuals with psoriasis on biologics. Two major concerns with live vaccinations in this patient population include the risk of impaired immunologic response and the increased incidence of HZ and its complications. However, recent evidence has shown that, despite these concerns, vaccinating patients with psoriasis on biologics with an HZ vaccine can be both safe and effective.

Journal

Journal of Psoriasis and Psoriatic Arthritis – SAGE

Published: Jun 1, 2013

There are no references for this article.